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Article info ABSTRACT  
Hepatitis Delta is severe and rapidly progressing form of viral hepatitis 
which leading to the liver cirrhosis and this infection is still an 
unresolved global health problem. The treatment of delta-virus infection 
is an unresolved problem. The application of the interferon 
preparations in case of delta-infection does not guarantee the efficacy 
of the treatment in the majority of patients, does not provide the stability 
of the elimination of the virus and gives a set of side-effects. New 
preparations with other mechanisms of the actions are now developing. 
These are nucleosides analogues and preparations with the specific 
mechanisms of action like Myrcludex B, Lonafarnib, REP 2139 which 
are in process of clinical tests. The combined therapy by the interferons 
and the nucleoside analogues seems to be perspective.  
 
Viral hepatitis remains the most urgent issue for the global public health care. The 
infectious diseases become cause of death for above 4 million people every year, while 
about 1 million people die from hepatitis B (HBV) and C (HCV) every year in the world, 
and even more infected people lose their ability to work. Losses connected with the viral 
hepatitis compose a significant share of the economic damage caused by the most 
common infectious diseases. Currently the role of understudied and poorly treatable 
mixed infection of hepatitis B with the delta agent is growing against the background of 
the rapid progress in treatment of the viral hepatitis C. 
In the world there are 400 million people infected with the hepatitis B virus, of 
which 15-25% (750 thousand) is fatal every year due to the liver cirrhosis complications 
and hepatocellular carcinoma. The share of HBV patients with a concomitant delta agent 
that dramatically complicates its natural course varies from below 1% to above 10% in 
different populations. Worldwide, 20 million people can be infected with the hepatitis 
Delta virus [1,13].  
In 1977, the Italian Doctor M. Rizetto reported discovery of a new Delta antigen in 
the patients with chronic hepatitis B [42]. Later it was defined that this antigen belongs to 
another pathogen of hepatitis, namely HDV, while the HDV virus genome was cloned 
and sequenced in 1986 [50].  
Epidemiology. 
The anti-HDV antibodies detection rate serves as an indicator of the chronic HDV 
prevalence. The regions can be conditionally assigned to one of four zones in terms of the 
Delta infection prevalence in the patients with hepatitis B: zones of high endemicity - the 
anti-HDV antibodies frequency composes above 60%; zones of medium endemicity - the 
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anti-HDV antibodies frequency composes 30-60%; zones of low endemicity - the anti-
HDV antibodies frequency ranges from 10 to 30%; zones of very low endemicity - the 
anti-HDV antibodies frequency composes below 10%.  
Areas of HDV infection high prevalence include Italy, certain regions of the Eastern 
Europe, the Amazon Basin, Venezuela, Colombia, certain regions of the Pacific, of 
Pakistan and of the Western Asia [44].  
The hepatitis Delta course undoubtedly depends on the HDV virus genotype. The 
HDV virus genetic diversity is associated with the geographical origin, while at the 
present eight HDV-I - HDV-8 genotypes have been identified [11,23].  
Genotype I is the most common and is often found in the United States, Russia, 
Africa, Asia and Brazil. HDV-2, previously known as genotype IIa, is found in Japan, 
Taiwan, and Russia. HDV-3 is common in the Amazon region, HDV-4 (old genotype 
IIb) is found in Taiwan and Japan [42,58]. HDV-5, HDV-6, HDV-7 and HDV-8 
genotypes are found in Africa. The HDV-3 genotype caused outbreaks of severe and 
peracute forms of hepatitis in the northeastern part of the South America. Studies prove 
that HDV-3 is common in the Amazon Basin. Obviously this HDV genotype appears to 
be more aggressive [5,40,41,47,51].  
According to the recent studies almost a third of the patients with HBV were 
infected with HDV in the region of northeastern part of the South America [6].  
In Europe the prevalence rate varies from 1% (Finland, Slovenia) to 25% 
(Romania). Since the HBV vaccination programs in the 1980s, HDV prevalence rates 
declined in many European countries, such as from 25% in 1983 to 9% in 2014 in Italy. 
The immigrants make up the majority of the patients with chronic HDV infection in the 
Central Europe. Thus, a study in Germany found that 75% of HDV-positive patients 
migrated from Turkey or the Eastern Europe [22]. 
The frequency of HDV markers detection among the HBsAg carriers was assessed 
in several regions of Russia. According to the authors the antibodies to HDV were 
detected in 1.3-5.5% of HBsAg (+) patients in the European part of Russia [46]. The 
Republic of Sakha (Yakutia) has the most common prevalence of the HDV infection, 
where the chronic HDV share in the etiological structure of chronic viral hepatitis 
composed 24.5% [45]. In some areas, the share of patients with antibodies to HDAg 
among HBsAg (+) patients reached 31% [35]. The HDV infection high level was 
recorded in the Astrakhan region, where 66.9% had HBsAg out of 151 patients with 
chronic diffuse liver diseases; while 74.5% of them showed HDV markers [37].  
 In a study conducted in the clinic named after E.M. Tareev in Moscow, for the 
period of 1994–2007, markers of active HDV infection were detected in 64 (19.5%) of 
327 HBsAg (+) patients (2). The HDV infection outbreak in the late 90s of the 20th 
century in the Samara region attracts attention, where the HDV detection rate in HBsAg 
(+) patients reached 39%, which is probably due to the large number of drug addicts in 
the epidemiological sampling [15].  
Virus Properties. HDV is a spherical formation with a diameter of 28-39 nm, in 
average of 36 nm. RNA - the genome and the HDV antigen - is located at the center of 
the particle. It is covered with HBsAg from above. The HDV genome is a single-
stranded, circular RNA consisting of an average of 1,700 nucleotides [33]. The HDV 
particle contains a delta antigen that exists in two forms: a large Delta antigen (L-HDAg) 
consisting of 214 amino acids and having a mass of 27 kDa and a small Delta antigen (S-
HDAg) with a length of 195 amino acid residues and a mass of 24 kDa [54]. Both N-
terminus forms have a helix, necessary for dimerization. Delta antigen dimers have an 
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arginine-rich motif that allows it to bind to viral RNAs. However, the L-HDAg extended 
C-terminus have four unique residues of cysteine serving as targets for farnesylation. 
After this post-translational modification, L-HDAg can interact with HBV surface 
proteins (HBsAg) and thereby facilitating the assembly of new virus particles. Small 
Delta antigen is necessary for viral RNA replication and functions in the early stages of 
infection [14]. 
The total amount of RNA HDV in one hepatocyte can reach from 100,000 to 
300,000 copies, which indicates a high rate of replication [8]. 
The HDV pathogenesis has the unique ability to use human RNA-dependent RNA 
polymerases to transcribe its own RNA without formation of the intermediate forms of DNA. 
Cell penetration and viral replication cycle: 
HDV hepatotropism and its ability to reproduce within hepatocytes is associated 
with co-infection HBV. The initial stages of the HDV interaction process with the 
hepatocyte take place due to HBsAg. 
The functional receptor for HBV and HDV is counter-transport peptide of the 
sodiumtaurocholate (NTCP). NTCP is located in the basolateral membrane of 
hepatocytes and its main role in vivo is transportation of the bile salts from portal blood 
to hepatocytes. This process is known to be vital for maintaining biliary acid 
homeostasis. NTCP is responsible for the majority of the hepatic bile salts, as well as for 
transportation of certain drugs and xenobiotics [20,34].  
 Viral infection is supported by amino acids involved in binding of bile acids. The 
interaction between NTCP and HBV/HDV is mediated by 75 N-terminal amino acid 
residues in the PreS1 domain of viral surface proteins and the binding sector on NTCP 
located on the outer layer of the cell membrane. Since the HBV and HDV shell structure 
is very similar, it can be assumed that the mechanisms of attachment to the target cell and 
penetration into it will be common for these viruses. In fact, most of the currently 
available information regarding the mechanisms of HBV penetration into the cell is 
obtained from HDV infection models [3,21].  
During replication, antigenomic RNA is found only in the nucleus and is 
synthesized in the nucleolus, while genomic RNA molecules synthesized in the 
nucleoplasm can be involved into another replication cycle in the nucleus or exported to 
the cytoplasm to assemble new viral particles [38].  
Three enzymatic activities are necessary for HDV RNA replicating: 
• polymerase activity for the oligomeric chains synthesis on ring matrices, when 
antigenomic matrix is synthesized in the genomic matrix in the first stage and the 
antigenome acts as a matrix for synthesis of the genome in the second stage; 
• ribozyme-dependent RNA-type activity for cutting these chains into monomers; 
• ligase  activity for closing the monomers in ring [12]. 
Unlike some RNA viruses with larger genomes, HDV has no its own RNA-
dependent RNA polymerase. Moreover, unlike other satellite viruses, HDV does not use 
the helper virus polymerase (that is, a virus, only in the presence of which formation of 
HDV virions is possible) and therefore relies entirely on the enzymes of the host cell. 
There is some evidence that host cell RNA polymerase II is involved in HDV replication. 
Obviously, HDV is able to make DNA-dependent RNA polymerase work with RNA. The 
mechanisms for such a switch are unclear to a significant extent. S-HDAg apparently is 
involved in switching the RNA polymerase II specificity; it can bind to RNA polymerase 
II and enhance transcription either directly stimulating elongation or leveling inhibitory 
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effects. DNA-dependent enzyme probably works with genomic RNA due to its partially 
double-stranded rod-like structure [3,38]. 
The antigenomic RNA is prepared during replication under influence of the cellular 
enzymes - Adenosine deaminase impacting RNA (ADAR1), which catalyzes the ST-stop 
codon mutation on the tryptophan codon (UGG) S-HDAg, which results in approximately 30 
amino acid elongation (depending upon genotype) [39]. The resulting mRNA leads to 
formation of the L-HDAg protein containing S-HDAg with a C-terminal amino acid 
elongation. This extension contains a signal on nuclear export and HBsAg binding fragment 
by the sector prenilylation in Cys211, which is post-translationally farnesylated by the 
cellular farnesyl transferase. Farnesylated L-HDAg is required for HDV assembly, as it 
interacts with the cytosolic HBsAg loop during shell formation [19,24]. 
Thus, membrane formation around HDV ribonucleoprotein requires farnesylation of 
the L-HDAg C-terminal sector, since it controls the interaction with the HBsAg S-sector. 
However, farnesylation of the C-terminal sector requires L-HDAg prinylation. HDV 
assembly is impossible in absence of these mechanisms. 
HDV virion formation requires HDV ribonucleoprotein coating with S- and L-
HBsAg, therefore HDV particles assembly is only possible in HBV co-infected cells. 
There are many questions having no answers concerning the HDV particles assembly and 
the cell exit. HDV particle assembly is possible only in co-infected HBV cells, since 
HBsAg is required for wrapping. However, HBsAg can also be synthesized by the 
defective HBV genomic integrals which are not encoding complete pregenomic RNA 
HBV, but still encoding HBV shell proteins with self-assembly [16]. Functional viral 
particles are wrapped by both L-HBsAg and S-HBsAg. Fundamentally, HDV coverage 
requires only S-HBsAg (unlike HBV, which also requires L-HBsAg), since L-HBsAg is 
crucial for the HDV virus infectivity; the particles covered only by S-HBsAg remain non-
infectious, although may contribute to "viral load" in the infected patients. Further on the 
wrapped particles are secreted from the cells. It remains unclear whether this happens by 
the classical secretion or through the multivesicular bodies (for instance, for HBV) [48].  
Unlike HBV requiring the cytoplasmic HBsAg domain for the particles release 
including the connecting sector between PreS1 and PreS2, HDV does not need this. 
Based on this, it was assumed that HDV predominantly releases sub-virus particles 
through the Golgi apparatus, rather than through a multi-vesicular body, like HBV [3].  









































1. HDV virus in Disse space; 2. NTCP interaction with PreS1 denome HBsAg; 3. HDV genome penetration into the
hepatocyte cytoplasm; 4. HDV genome penetration into the hepatocyte nucleus; 5. HDV genome replication; 6. synthesis
of HDV mRNA by antigenomic RNA HDV; 7. Pre S 1 and Pre S2 domains synthesis using HBV cсс DNA; 8. HDV genome
released into cytoplasm; 9. S-HD Ag and L-HD Ag synthesis using HDV mRNA; 10. L-HDAg prnylation; 11. HDV genome
wrapping with S-HD Ag antigens and prenylated L-HD Ag; 12. HDV genome wrapping with S-HD Ag antigens and
prenylated L-HD Ag in HBsAg; 13. ready HDV virion released from the hepatocyte.
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As noted, taurocholatesodium peptide (NTCP) is responsible for transportation of 
the bile salts; however, in presence of HBV and HDV viruses, it can also be used to 
penetrate the virus genetic material into the cell. Nevertheless, it remains unclear whether 
these two NTCP functions are independent or interfere with each other. 
In his research, Huan Yan discovered that the pre-S1 domain actively blocks 
absorption of NTCP bile salts substrates. This, in turn, leads to accumulation of the bile 
salts substrates, which inhibited the HBV and HDV penetration into the cell to varying 
degrees. These results in deeper understanding of interaction between the shell proteins 
of HBV and NTCP proving that bile acids and derivatives of such may7 contribute to 
blocking of HBV and HDV [52]. 
The studies of the authors proved the tauro-conjugate form of ursodeoxycholic acid 
(TUDCA) to be an inhibitor of HBV and HDV viral infections. Given the above 
mechanism, several clinical observations proved that long-term use of the bile salts, in 
particular, TUDCA, leads to improvement in the liver function and affects the viral load 
in patients with hepatitis B [9,17].  
In his studies, Zhang Z, described the interferon (IFN) promotion during HDV 
infection and assessed the IFN effect on the HDV replication. The author’s study analysis 
proved that active replication of HDV, but not of HBV, induces IFN-β and IFN-λ in the 
infected hepatocyte cells; however, this impacts insignificantly the HDV replication. 
During the prolonged infection, IFN levels gradually decreased in both HepG2NTCP cell 
lines and HepaRGNTCP cell lines of the study models. According to the author, this 
mechanism explains adaptation to interferons in the HDV replication. In addition, IFN 
Type I or III treatment does not block HDV replication [53]. 
However, it should be noted that in his study, Katashiba Y., indicates that IFN is 
mainly stimulated in DNA containing infections, while IL-12 induction predominates in 
RNA containing infections. Since HDV consists of a single-stranded RNA molecule, it is 
not expected that it will stimulate IFN [30]. 
We believe that the above disagreements of the authors can be explained by the fact 
that replication possibly induces IFN synthesis inside the hepatocyte in case of the HBV 
virus, while HBV suppression blocks IFN synthesis. Further, HDV is not able to induce 
IFN, namely induces IL-12, which in turn indirectly induces IFN-gamma; however, by 
this time HDV becomes resistant to IFN. In addition, HDV blocks IFN signaling to a 
nearby hepatocyte. 
Clinical Findings 
Studies of the recent 40 years have proved that a significant part of liver diseases, 
previously considered as the infection result with the hepatitis B virus (HBV), are 
actually the result of simultaneous infection with B and Delta viruses (HDV). The disease 
course, as a rule, is characterized by a particular severity. However, a Delta infection 
exists in several forms that differ in clinical characteristics, frequency, outcome. The 
virus can cause conditions that are similar to the acute viral hepatitis (AVH), as well as to 
the typical forms of chronic hepatitis (CH) and liver cirrhosis (LC). The asymptomatic 
carriage of HDV is also possible. WHO estimated that at least 20 million of HBsAg 
carriers in the world simultaneously had Delta virus. Currently, this number is estimated 
at 25 million [1].  
According to B. Pinarbasi Simsek et al. the HBsAg and HDVRNA concentrations 
in the patients with HBV and HDV infection is reliable and correlated positively 
(p=0.043). All patients examined had various HDV viral load not correlating with 
biochemical and histological activity or the stage of fibrosis. Serum transaminase 
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concentration and histological had no correlation between HBVDNA-negative and 
positive patients with chronic HDV (p> 0.05), while HBsAg concentrations had minor 
difference in patients with positive and negative HBVDNA (p> 0.05). HBsAg levels 
were significantly higher in patients with HBeAg-positive chronic HDV than in patients 
with HBeAg-negative chronic HDV, but being the same levels in patients with chronic 
HDV and HBeAg-negative chronic HBV. The histological activity and fibrosis stage 
were significantly higher in chronic HDV than in patients with chronic HBV; however, 
such were not affected by the HDV and HBV viremia levels [4]. 
Background in the Republic of Uzbekistan. Musabaeva E.I. et al. presented the 
effect of IL28B-gene genetic variations on the risk of the liver cirrhosis developing and 
possibility to predict the disease outcome in HDV-infected patients. The genotype 
rs8099917 in IL28B locus TaqMan SNP was defined by genotyping in 94 individuals, 
including 72 patients with liver cirrhosis (LC) associated with HDV infection aiming to 
assess the effect of IL28B rs8099917 SNP among the studied groups. A group of 22 
patients with HBV LC etiology was taken for comparison. The study results proved that 
the genotypes distribution in HDV-induced LC was significantly different from the HBV-
etiology LC, both as per rs8099917 TT genotype (p<0.001) and as per rs8099917 TG 
genotype (p<0.001). Traditional risk factors for LC (sex, age, viral load, comorbidities) 
had insignificant effect on the chronic viral hepatitis outcome. The studies results proved 
that the genotypes distribution in HDV-induced LC was significantly different from the 
HBV etiology LC, both as per TT-genotype and TG-genotype. Thus, genetic analysis is a 
promising method for non-invasive diagnosis of the risk of LC developing [31]. 
Interesting studies were conducted for the viral hepatitis B and mixed hepatitis in 
children. Inoyatovoy F.I. et al. conducted the clinical analysis in children with the chronic 
HBV, having refractory variant of anemia of inflammation (AI), the pathogenetic 
manifestation of which was development of iron overload syndrome (IOS). It was 
revealed that, the disease progressive forms frequency increased with persistent 
prevalence of asteno-vegetative, hemorrhagic syndromes and severe hepatosplenomegaly 
secondary to increasing severity of IOS. At the same time, the leading biochemical 
syndromes were: presence of the cytolysis with prolonged hyperfermentemia, 
endotoxemia and mesenchymal-inflammatory syndrome [28].  
The frequency of clinical manifestations of delayed sexual development (DSD) and 
the functional status of the pituitary-gonadal system in boys with chronic hepatitis B 
(chronic HBV) was studied depending on the activity and duration of the disease. The 
incidence of DSD among the examined boys composed 60.4%. The serum basal levels of 
gonadotropic and sex hormones - FSH, LH, T, E. were studied. It was proven that 
chronic HBV as a chronic infectious process negatively affects development of the 
reproductive health of boys [29]. 
74.6% of cases (versus 22.2% of healthy children) of examination of patients with 
chronic hepatitis B revealed psychological changes that were characterized by 
impairments in the intellectual (66.9%), emotional (66.1%) and behavioral (71.6 %) 
spheres. At the same time, the level and direction of psychological manifestations were 
conditioned by the age features of the sick children development [26]. 
The activity of lipid peroxidation (POL) and the antioxidant system (AOS) 
effectiveness in patients with chronic mixed hepatitis (chronic MH) with persistence of 
HB-, HC- and HD viruses were studied. It was revealed that mixed infections with 
hepatotropic viruses exacerbate membrane-destructive processes in cells, contributing to 
development of severe forms of the disease. Prolonged hyperfermentemia and disruption 
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of the relations between the POL/AOS processes indicators as well as development of the 
persistent intensification of the POL reactions, especially with triple (B + C + D) 
infection are characteristic biochemical signs of chronic mixed hepatitis (CMH) in 
children. As a result, destabilization of the membrane lipid structure was manifested by 
increase in cholesterol, triglycerides and decrease in phospholipid levels (27). 
The next goal of the authors' work was to study the clinical and biochemical 
features and marker profile in children with the chronic viral mixed hepatitis (chronic 
VMH). 480 patients aged from 3 to 14 years were observed. Among them, 120 (25.6%) 
children had mixed hepatitis, 86 (71.7%) had HBV and HCV markers, 34 (28.3%) had 
HBV, HCV and HDV markers. Virological verification was performed by ELISA and 
PCR. The results of the clinical examination of children, with chronic viral mixed 
hepatitis allowed to conclude that the disease severity depends upon the persistence and 
replication of two/three viruses. This is clearly reflected in the high frequency and 
severity of clinical syndromes, such as asthenovegetative, hemorrhagic and cholestatic 
with prevalence of large sizes of the liver and spleen in children, infected with two and 
especially three viruses. The clinical symptoms are 1.9 times less frequent than those in 
patients with mixed infection and are relatively moderate if there is only one virus 
(HBV). This is probably conditioned by absence of the additional damage factor (other 
viruses) and ability to integrate HBV into the hepatocyte genome. Cytolysis, 
endotoxemia and cholestasis syndromes are the leading biochemical indicators of liver 
damage in chronic viral mixed hepatitis [25]. 
In 2003-2004, the studies of T.A. Daminov et al. defined HBV genotypes in 
children suffering from chronic viral hepatitis B (HBV). All DNA-HBV-positive patients 
(n=40) were genotyped for the hepatitis B virus. Studies proved that children suffering 
from chronic viral hepatitis B were infected with various HBV genotypes, with 
prevalence of the O (77.5%) and A (15%) genotypes [10]. 
The studies of Khikmatullaeva A.S. (32), presents incidence of the latent HBV 
infection. The selective screening studies were conducted in various regions of the 
Republic aiming to diagnose and assess the viral hepatitis prevalence rate. In total, 1,645 
blood samples of conditionally healthy individuals never consulted for liver disease 
before were examined for presence of HBsAg and AntiHCV in the blood plasma. 
According to the author, the highest percentage of HBs antigenemia detection was in the 
Southern, Southwestern and Central regions, where positive results composed on average 
12%. Whereas, positive HBsAg results averaged 10% in the Eastern, Northern and 
Northwestern regions. However, these patients were never examined for presence of 
AntiHDV unfortunately.  
Possible Therapy. Timely therapy for HDV is very important, since the complex of 
therapeutic measures aiming to reduce the fibrotic processes progression in the liver 
contributes to prolong the patients' life and preserve the ability to work. According to 
many researchers, currently interferon is the only approved drug in treatment of HDV. 
However, there are few data on the effect of interferons on HDV in human hepatocytes.  
The studies of Giersch K. evaluated the effect of pegylated interferon alpha (peg-
IFNα) and lambda (peg-IFNλ) compared with the HBV polymerase inhibitor entecavir 
(ETV) on all markers of HDV infection. After infection of mice with HDV virus, HDV 
RNA was detected by PCR intrahepatic. Peg-IFNα and peg-IFNλ were found to reduce 
HDV viremia (1.4 log and 1.2 log, respectively) and serum HBsAg levels (0.9-log and 
0.4-log, respectively). Both interferons significantly reduced intrahepatic levels of 
genomic and antigenomic HDV RNA. Entecavir-mediated suppression of HBV 
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replication (2,1-log) had no significant effect on the HBsAg levels and HDV performance 
or release of such from the hepatocyte. Reduction in viremia reflected the intrahepatic 
decline in all HDV markers, including the antigenomic pattern, indicating that 
intracellular HDV clearance was achieved [18]. 
New directions in treatment of the chronic HDV is development of drugs that 
inhibit binding of the Delta agent and the hepatitis B virus, for instance, Myrcludex B. 
The mechanism of the substance action is ability to firmly bind to a specific hepatocyte 
receptor, NTCP, located on the cell surface, which in turn prevents the contact of HBsAg 
with the hepatocyte, which preventing the viral genome from penetrating into the cell. 
Myrcludex B is hepatotropic in nature and specifically binds to NTCP on the cell 
membrane and is accumulated on the sinusoidal membrane of hepatocytes after 
intravenous or subcutaneous administration. Myrcludex B inhibits NTCP bile acid 
transporter function, indicating HBV/HDV receptor blockade [36]. 
 












Taking into account the mechanism of the Myrcludex B action, it can be assumed 
that the medicine is able to block transportation of the bile acids, while its side effects 
may be associated with the impaired bilirubin metabolism. 
In addition, a drug, Lonafarnib, is currently studied. It affects the post-translational 
modification processes of the Delta agent antigens, in particular, C-terminus of the L-
HDVAg molecule, which links the HDV RNA nucleocapsid to the HBsAg virus. 
Lonafarnib prevents farnesylation of the C-terminal residue of Cys211 in L-HDAg, 
which are directly related to the HDV assembly. Consequently, unfarnate L-HDAg is not 
able to bind to HBsAg. HDV gene not wrapped by HBsAg cannot escape from the 
hepatocyte and leads to decrease in hepatocyte infection in the liver [43]. 
However, the Lonafarnib effect indicates that the inhibiting farnesylation process 
can accelerate cytotoxic effects in the hepatocyte. Replicated HDV genomes, 
intermediate products within the hepatocyte or enhanced immune-mediated death of 
hepatocytes are accumulated.  
Scheme No.2. The mechanism of the Lonafarnib action. 
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Analogs of nucleotides and nucleosides, as mentioned above, are ineffective in 
suppressing the replication of HDV RNA. However, this therapy should be considered 
for the patients with active HBV DNA replication.  
The newest drug REP 2139, the mechanism of action of which is aimed at blocking 
of the ready HBV or HDV virion release from the infected hepatocyte [43]. 
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The effect of REP 2139, like the effect of Lonafarnib, can lead to accumulation of 
the replicable HDV genomes, intermediate products within the hepatocyte, or enhanced 
immune-mediated death of hepatocytes.  
Discussion 
There are no results on HDV genotypes in the Republic of Uzbekistan. Once the 
level of the HDV infection endemicity is established and the HDV genotypes circulating 
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in the republic are defined, it will be possible to predict the clinical course and outcomes 
of the disease with mixed HBV + HDV infection.  
It is known that IFN-α and INF-γ induce when DNA containing viruses are infected, 
while IL-12 induction prevails when RNA is infected with viruses. Induction of IFN-α 
and INF-γ is also detected with the HDV infection, although endogenous interferons do 
not affect the replication of HDV. The question of the mechanism and pathogenic 
significance of the induction of IFN-α and INF-γ in the HDV infection remains open.  
The latest medicines developed to date do not completely resolve the problem in 
treatment of the patients with HBV + HDV and elimination of the HDV virus from the 
body. These medicines have only a temporary effect, but exhibit side effects. Myrcludex 
B is able to block transportation of the bile acids, while its side effects may be associated 
with the impaired bilirubin metabolism. At the same time administration of the 
Lonafarnib and REP 2139 will cause accumulation of the replicated HDV genomes, 
intermediate products inside the hepatocyte, or enhanced immuno-mediated death of the 
hepatocytes. 
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